检索结果-南通市图书馆

Genetic signatures of ERCC1 and ERCC2 expression,along with SNPs variants,unveil favorable prognosis in SCLC patients undergoing platinum-based chemotherapy

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

oncology Research 2025年第1期33卷 45-55页

作者： ENRICO CALIMAN SARA FANCELLI FEDERICO SCOLARI ADRIANO PASQUI CLARA MANNESCHI DANIELE LAVACCHI FRANCESCA MAZZONI FRANCESCA GENSINI VALERIA PASINI CAMILLA EVA COMIN LUCA VOLTOLINI SERENA PILLOZZI LORENZO ANTONUZZO Clinical oncology unit Careggi University HospitalFlorence50134Italy Department of Experimental and Clinical Medicine University of FlorenceFlorence50134Italy Department of Health Sciences University of FlorenceFlorence50134Italy Medical oncology unit Careggi University HospitalFlorence50134Italy Department of Experimental and Clinical Biomedical Sciences“Mario Serio” University of FlorenceFlorence50134Italy Section of Anatomic Pathology Department of Health SciencesUniversity of FlorenceFlorence50139Italy Section of Surgery Histopathology and Molecular PathologyUniversity of FlorenceFlorence50139Italy Thoracic Surgery unit Careggi University HospitalFlorence50134Italy

Background:Platinum chemotherapy(CT)remains the backbone of systemic therapy for patients with smallcell lung cancer(SCLC).The nucleotide excision repair(NER)pathway plays a central role in the repair of the DNA damage exerted by platinum *** in this repair mechanism may affect patients’*** and Methods:We conducted a retrospective analysis of data from 38 patients with extensive disease(ED)-SCLC who underwent platinum-CT at the Clinical oncology unit,Careggi University Hospital,Florence(Italy),from 2015 to *** expression analysis and single nucleotide polymorphism(SNP)characterization of three NER pathway genes—namely ERCC1,ERCC2,and ERCC5—were performed on patient tumor ***:Overall,elevated expression of ERCC genes was observed in SCLC patients compared to healthy *** with low ERCC1 and ERCC5 expression levels exhibited a better median progression-free survival(mPFS=7.1 vs.4.9 months,p=0.39 for ERCC1 and mPFS=6.9 vs.4.8 months,p=0.093 for ERCC5)and overall survival(mOS=8.7 vs.6.0 months,p=0.4 for ERCC1 and mOS=7.2 vs.6.2 months,p=0.13 for ERCC5).Genotyping analysis of five SNPs of ERCC genes showed a longer survival in patients harboring the wild-type genotype or the heterozygous variant of the ERCC1 rs11615 SNP(p=0.24 for PFS and p=0.14 for OS)and of the rs13181 and rs1799793 ERCC2 SNPs(p=0.43 and p=0.26 for PFS and p=0.21 and p=0.16 for OS,respectively)compared to patients with homozygous mutant ***:The comprehensive analysis of ERCC gene expression and SNP variants appears to identify patients who derive greater survival benefits from platinum-CT.

关键词： Small cell lung cancer(SCLC) Nucleotide excision repair(NER)pathway ERCC genes Single nucleotide polymorphisms(SNPs) Platinumchemotherapy(CT)

Combination therapy strategy based on selective internal radiation therapy as conversion therapy for inoperable giant hepatocellular carcinoma:A case report

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal oncology 2025年第3期17卷 410-417页

作者： Ming-Zhi Hao Hai-Lan Lin Yu-Bin Hu Qi-Zhong Chen Zhang-Xian Chen Lin-Bin Qiu Duan-Yu Lin Hui Zhang De-Chun Zheng Zhu-Ting Fang Jing-Feng Liu Department of Tumor Interventional Radiology Clinical Ocology School of Fujian Medical UniversityFujian Cancer HospitalFuzhou 350014Fujian ProvinceChina Department of oncology and Vascular Interventional Radiology Clinical Oncology School of Fujian Medical UniversityFuzhou 350014Fujian ProvinceChina Department of Nuclear Medicine Clinical Oncology School of Fujian Medical UniversityFuzhou 350014Fujian ProvinceChina Department of Hepatopancreatobiliary Surgical oncology Clinical Oncology School of Fujian Medical UniversityFujian Cancer HospitalFuzhou 350014Fujian ProvinceChina Department of Radiology Clinical Oncology School of Fujian Medical UniversityFujian Cancer HospitalFuzhou 350014Fujian ProvinceChina Department of oncology and Vascular Interventional Radiology Clinical Oncology School of Fujian Medical UniversityFujian Cancer HospitalFuzhou 350014Fujian ProvinceChina Department of Hepatobiliary Surgery Clinical Oncology School of Fujian Medical UniversityFujian Cancer HospitalFuzhou 350014Fujian ProvinceChina

BACKGROUND Hepatocellular carcinoma(HCC)has become a growing health concern *** invasion and high tumor burden are key factors limiting the curative effect of selective internal radiation therapy(SIRT).CASE SUMMARY This case study reports a 49-year-old woman who was diagnosed with China Liver Cancer Staging(CNLC)IIIa HCC and>15 cm tumor ***,due to insufficient future liver remnant and vascular invasion,the tumor was unresectable;however,radical hepatectomy was performed after successful conversion therapy with SIRT using yttrium-90(90Y)resin microspheres followed by hepatic arterial infusion chemotherapy(HAIC)with tyrosine kinase inhibitor(TKI)and anti-programmed death-1(PD-1)*** using 90Y resin microspheres was given by the right hepatic artery and chemoembolization was simultaneously performed in the tumor’s feeding vessels from the right diaphragmatic *** was followed every three weeks with lenvatinib and *** 4 months post-SIRT,the tumor was downstaged to CNLC Ib and the patient successfully underwent *** histopathological examination of the resected specimen showed extensive *** This case study provides evidence for an integrated treatment strategy combining SIRT and HAIC with TKI and anti-PD-1 antibodies for patients with large HCC and microvascular *** confirmatory trials are required in the future.

关键词： Selective internal radiation therapy Hepatic arterial infusion chemotherapy Yttrium-90 resin microspheres Hepatocellular carcinoma Conversion therapy Case report

Assessment of new pathological markers in early stage colon cancer:Insights and limitations

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal oncology 2025年第3期17卷 113-121页

作者： Bulent Erdogan Fatma Elif UsturalıKeskin ErkanÖzcan Ahmet Küçükarda Ali Kaan Güren Osman Köstek Bekir Muhammet Hacioglu Hilmi Kodaz Department of Medical oncology Division of Medical OncologyDepartment of Internal MedicineTrakya University School of MedicineEdirne 22000Türkiye Department of Pathology Trakya University School of MedicineTrakya UniversityEdirne 22000Türkiye Division of Medical oncology Trakya University School of MedicineEdirne 22000Türkiye Division of Medical oncology Department of Internal MedicineTrakya University School of MedicineEdirne 22000Türkiye Division of Medical oncology Department of Internal MedicineMarmara University School of MedicineMarmara UniversityIstanbul 34000Türkiye Division of Medical oncology Department of Internal MedicineMarmara University School of MedicineIstanbul 34000Türkiye Department of Medical oncology Acibadem Eskisehir HospitalEskisehir 26130Türkiye

BACKGROUND The decision to administer adjuvant chemotherapy to patients with local stage depends on specific high-risk features that are T4 tumor stage,presence of perineural invasion,lymphovascular invasion,poorly differentiated tumor histology,inadequate lymph node sampling(fewer than 12 lymph nodes),and evidence of tumor perforation or ***-stroma ratio,tumor infiltrating lymphocytes(TIL),Crohn-like reaction(CLR),desmoid reaction,poorly differentiated clusters(PDC)are new pathological markers that are being *** To examine the relationship between new pathological markers and defined high METHODS We evaluated 155 patients with the diagnosis stage I and II colorectal cancer between the years 2007 and 2021 who were treated at Trakya University Hospital,Department of Medical *** divided those with and without high-risk factors into two *** examined the relationship of new pathological markers with these groups and with pathological markers in risk *** There was no statistically significant correlation between presence of TIL,presence of PDC,presence of tumor budding,presence of CLR,presence of desmoid reaction and low and high-risk groups according to the degree of those with PDC(P=0.82,P=0.51,P=0.77,P=0.37,P=0.83,respectively).In addition,no statistically significant correlation was found between the tumor-stroma ratio and low and high risk groups(P=0.80).We found a statistically significant correlation between the presence of PDC and the presence of PDC grade 3 and T stage(P=0.001,P=0.001,respectively).It was determined that the presence of PDC and the frequency of grade 3 PDC increased with the advanced T *** No relationship was found between the presence of new pathological markers and high-low risk *** we examined the relationship between new and old pathological markers,only the frequency of detection of PDC and PDC grade 3 was found to be correlated with advanced T stage.

关键词： Colon cancer Early stage Risk factors New pathological markers Tumor-stroma ratio Tumor infiltrating lymphocytes Crohn-like reaction Desmoid reaction Poorly differentiated clusters

Copper-catalyzed C–H bond functionalization enabled by programmed alternating current

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Science China Chemistry 2025年第1期68卷 10-11页

作者： Zhoumei Tan Kun Xu Chengchu Zeng Beijing Key Laboratory of Environmental and Viral oncology College of Chemistry and Life ScienceBeijing University of TechnologyBeijing 100124China

Synthetic electrochemistry has been selected as one of the Top Ten Emerging Technologies in Chemistry in 2023 by International Union of Pure and Applied Chemistry(IUPAC)^([1]).It has emerged as a sustainable platform for organic synthesis and has exhibited a wide range of applications from academia to industry^([2]).However,electrosynthesis has been predominantly performed by using direct current(DC).

关键词： catalyzed Copper IUPAC

Ubiquitin-specific protease 1 facilitates tumor immune escape from natural killer cells and predicts the prognosis in small cell lung cancer

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

oncology Research 2025年第1期33卷 213-224页

作者： SHIQIN JIANG YICHUN TANG FENG MA YUCHUN NIU LEI SUN Department of Clinical Pharmacy Shenzhen Hospital of Integrated Traditional Chinese and Western MedicineShenzhen518104China Department of Pathology Zhujiang HospitalSouthern Medical UniversityGuangzhou510280China Department of Radiation oncology The First People’s Hospital of FoshanFoshan528000China Department of oncology The First Affiliated Hospital of Jinan UniversityJinan UniversityGuangzhou510630China Department of oncology The First Dongguan Affiliated HospitalGuangdong Medical UniversityDongguan523721China

Objective:Small cell lung cancer(SCLC)is commonly recognized as the most fatal lung cancer *** substantial advances in immune checkpoint blockade therapies for treating solid cancers,their benefits are limited to a minority of patients with *** the present study,novel indicators for predicting the outcomes and molecular targets for SCLC treatment were ***:We conducted bioinformatics analysis to identify the key genes associated with tumor-infiltrating lymphocytes in *** functional role of the key gene identified in SCLC was determined both in vitro and in ***:A significant correlation was observed between patient survival and CD56dim natural killer(NK)cell ***,we noted that the hub gene ubiquitin-specific protease 1(USP1)is closely correlated with both CD56dim NK cells and overall survival in *** analysis revealed that USP1 is upregulated in *** addition,gene set enrichment analysis revealed that USP1 overexpression hinders NK cell-mediated immune *** co-cultivating NK-92 cells with SCLC cells,we demonstrated that NK cell cytotoxicity against SCLC could be improved either via USP1 knock-down or pharmacological ***,using a nude-mice xenograft tumor model,we noted that USP1 inhibition effectively suppressed tumor proliferation and increased the expression of NK cell-associated ***:Our study findings highlight the importance of NK cells in regulating ***1 overexpression can inhibit NK cell-mediated immunity;therefore,USP1 may serve not only as a prognostic biomarker but also as a potential molecular target of SCLC therapy.

关键词： Ubiquitin-specific protease 1(USP1) Natural killer(NK)cell Small cell lung cancer(SCLC) Prognosis Immune escape

Multiple pseudoprogressions during ongoing immunotherapy-based treatment of advanced gastric neuroendocrine carcinoma:A case report and review of literature

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal oncology 2025年第3期17卷 431-442页

作者： Yan-Hua Mou Juan Zhang Hui Shen Jing Yu Lan Han Hui Li Qing-Feng Li Department of oncology Xiangyang Central HospitalAffiliated Hospital of Hubei University of Arts and ScienceXiangyang 441021Hubei ProvinceChina Institute of oncology Hubei University of Arts and ScienceXiangyang 441021Hubei ProvinceChina

BACKGROUND Gastric neuroendocrine carcinomas(NECs)exhibit aggressive features,such as rapid growth,higher rate of metastasis,and a generally unfavorable prognosis compared to gastric *** a result,therapeutic options for NECs remain limited,contributing to the poor prognosis of *** has emerged as a promising treatment strategy and demonstrated the potential to partially improve the survival and prognosis of patients with ***,the unique clinical response termed pseudoprogression(PsP)has garnered considerable attention in the context of *** SUMMARY Presented here is a case of NEC recurrence five and a half months after radical gastric *** 45-year-old male patient underwent combination treatment involving a PD-1 blocker and tyrosine kinase inhibitors and encountered two instances of PsP during *** patient ultimately achieved a durable treatment response without altering his treatment regimens,resulting in a substantial therapeutic *** This case report aimed to provide the authors’experience with the diagnosis of PsP and treatment strategies for PsP in ongoing immunotherapy.

关键词： Gastric neuroendocrine carcinomas Pseudoprogression Immunotherapy Teprotumumab Case report

Combination of fruquintinib with venetoclax for the treatment of colorectal cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

oncology Research 2025年第1期33卷 225-234页

作者： WEI ZHANG WEICHENG WANG RUI WANG XIAO HAN LIJUN ZHU WENJIE GUO YANHONG GU Department of oncology The First Affiliated Hospital of Nanjing Medical UniversityNanjing210029China State Key Laboratory of Pharmaceutical Biotechnology School of Life SciencesNanjing UniversityNanjing210023China Department of oncology The Affiliated Taizhou People’s Hospital of Nanjing Medical UniversityTaizhou225300China

Background:As a novel blocker of vascular endothelial growth factor receptor(VEGFR),fruquintinib has been approved for treating colorectal cancer(CRC).However,its dosage and therapeutic efficacy are limited by its widespread adverse ***,recognized as the initial inhibitor of B-cell lymphoma protein 2(BCL2),has shown potential in boosting the effectiveness of immunotherapy against *** study investigated the efficacy and mechanisms of fruquintinib combined with venetoclax in treating *** and Materials:We developed a colon cancer mouse model with the CT26 colon cell line to demonstrate fruquintinib and venetoclax’s efficacy against *** we employed various techniques to evaluate different aspects of the experimental *** was used to detect cell proliferation and angiogenesis in tumor *** blot analysis was utilized to examine the occurrence of cell apoptosis,and flow cytometry to quantitate immune cells within the tumor ***,immunofluorescence was employed to measure cytokine ***:The strongest inhibition on tumor growth was achieved by the combination of fruquintinib with venetoclax,as opposed to individual drug *** was found to amplify the impact of fruquintinib,leading to decreased cancer cell proliferation,increased cancer cell apoptosis,lowered angiogenesis,better vascular structure normalization,and improved immune cell ***:Our findings indicate that the addition of venetoclax enhances the impact of fruquintinib on vascular normalization and modulation of the tumor immune *** study presents the justification for utilizing the fruquintinib and venetoclax combination in treating *** holds promise in being assimilated into anticancer medications for CRC.

关键词： Colorectal cancer(CRC) B-cell lymphoma protein 2(BCL2) Venetoclax Vascular endothelial growth factor receptor(VEGFR) Fruquintinib Anti-angiogenesis Immunotherapy

Improved treatment of colorectal liver metastases by early response evaluation and regimen adjustment: a prospective study of clinical functional MR-based modeling

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Biology & Medicine 2025年第02期 166-176页

作者： Wenhua Li Huan Zhang Zhe Gong Yue Li Zhiyu Chen Xiaodong Zhu Mingzhu Huang Zhe Zhang Chenchen Wang Lixin Qiu Qirong Geng Jinjia Chang Xiaoying Zhao Xuedan Sheng Wen Zhang Tong Tong Weijian Guo Department of Medical oncology Fudan University Shanghai Cancer Center Department of oncology Shanghai Medical College Fudan University Department of Radiology Fudan University Shanghai Cancer Center Department of Radiation oncology Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences

Objective: The aim of the study was to evaluate the feasibility of functional MR in predicting the clinical response to chemotherapy in patients with colorectal liver metastases(CLM).Methods: A total of 196 eligible patients were enrolled in the study between August 2016 and January 2023. Functional MR was performed at baseline and after one cycle of chemotherapy. The diffusion kurtosis radiomic texture features were extracted and a signature model was built using the R package. The initial 100 cases were designated as the training set, the following 48 cases were designated as the validation set, and the final 48 cases were designated as the intervention validation ***: Good performance for the response prediction(AUC = 0.818 in the training set and 0.755 in the validation set) was demonstrated. The objective response rates(ORRs) in the high-risk subgroup were significantly lower than the low-risk subgroup in the training and validation sets. Worse progression-free survival and overall survival rates were noted in the high-risk population. In the intervention set 22.9%(11/48) of the chemotherapy regimens for patients were changed in response to the model-predicted results and the ORR reached 77.1%(37/48), which was significantly higher than the training and validation sets [47.97%(71/148); P = 0.000].Conclusions: A functional MR signature effectively predicted the chemotherapy response and long-term survival. The adjustment of the regimen guided by the model significantly improved the ORR.

关键词：

Diagnosis and Management of Pediatric Brain Tumors in Togo

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Open Journal of Modern neurosurgery 2025年第1期15卷 56-64页

作者： Agbéko Komlan Doléagbénou Ablavi Oyénitwa Solange Adani-Ifè Ben Ousmane Djoubairou Ama Paula Adjidjonou Essossinam Kpélao Facult des Sciences de la Sant University of Lom Lom Togo neurosurgery unit Regional Hospital Center of Lom Commune Lom Togo neurosurgery unit Sylvanus Olympio Teaching Hospital Lom Togo Medical oncology unit Sylvanus Olympio Teaching Hospital Lom Togo neurosurgery unit Military Hospital of Yaound Yaound Cameroon

Background: Pediatric brain tumors (PBT) are among the most common childhood neoplasms worldwide, but their management in low- and middle-income countries (LMICs) remains under-documented. Limited access to specialized care, diagnostic tools, and adjuvant therapies poses significant challenges in sub-Saharan Africa, including Togo. Objective: This study reviews the management of pediatric brain tumors in Togo. Methods: We conducted a retrospective study in the neurosurgery department at Sylvanus Olympio Teaching Hospital between November 2017 and December 2022. Demographic, clinical, radiographic, operative, pathology, and outcome data were collected and analyzed. Results: Eighteen patients had histologically verified brain tumors. Ages ranged from 1 to 15 years (mean: 7.73 ± 4.28), with a sex ratio of 1. Symptoms of raised intracranial pressure were present in 83.4% of cases. The mean interval to presentation was 22 ± 5.32 months. Tumors were supratentorial in 66.7% of cases. Total tumor removal was achieved in 61.1%. Astrocytoma was the most common histological diagnosis, followed by ependymoma and medulloblastoma. Five patients (27.8%) died within the first month post-surgery. The estimated 5-year survival rate was 43% ± 5.4%. Conclusion: Delayed diagnosis, insufficient infrastructure, and limited access to radiotherapy and chemotherapy contribute to poor outcomes. Improving neurosurgical capacity, infrastructure, and financial support could enhance survival and outcomes for pediatric brain tumor patients in Togo.

关键词： Pediatric Brain Tumors Togo neurosurgery Sub-Saharan Africa